JP2024517942A - Ｇタンパク質共役受容体の調節剤 - Google Patents

Ｇタンパク質共役受容体の調節剤 Download PDF

Info

Publication number
JP2024517942A
JP2024517942A JP2023569936A JP2023569936A JP2024517942A JP 2024517942 A JP2024517942 A JP 2024517942A JP 2023569936 A JP2023569936 A JP 2023569936A JP 2023569936 A JP2023569936 A JP 2023569936A JP 2024517942 A JP2024517942 A JP 2024517942A
Authority
JP
Japan
Prior art keywords
compound
group
independently selected
optionally substituted
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517942A5 (https=
Inventor
ダニエル アーランソン
レイモンド ブイ． フッチニ
スティグ ハンセン
ジェフ アイウィッグ
シャム クリシュナン
エンリケ モヤ
スティーヴン セトファー
Original Assignee
カーモット セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カーモット セラピューティクス インコーポレイテッド filed Critical カーモット セラピューティクス インコーポレイテッド
Publication of JP2024517942A publication Critical patent/JP2024517942A/ja
Publication of JP2024517942A5 publication Critical patent/JP2024517942A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Holo Graphy (AREA)
  • Gyroscopes (AREA)
  • Amplifiers (AREA)
JP2023569936A 2021-05-13 2022-05-13 Ｇタンパク質共役受容体の調節剤 Pending JP2024517942A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188342P 2021-05-13 2021-05-13
US63/188,342 2021-05-13
PCT/US2022/029305 WO2022241287A2 (en) 2021-05-13 2022-05-13 Modulators of g-protein coupled receptors

Publications (2)

Publication Number Publication Date
JP2024517942A true JP2024517942A (ja) 2024-04-23
JP2024517942A5 JP2024517942A5 (https=) 2025-05-22

Family

ID=82019613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569936A Pending JP2024517942A (ja) 2021-05-13 2022-05-13 Ｇタンパク質共役受容体の調節剤

Country Status (20)

Country Link
US (2) US12281149B2 (https=)
EP (1) EP4337682A2 (https=)
JP (1) JP2024517942A (https=)
KR (1) KR20240007251A (https=)
CN (1) CN117980325A (https=)
AU (1) AU2022272251A1 (https=)
BR (1) BR112023023559A2 (https=)
CA (1) CA3220005A1 (https=)
CL (1) CL2023003369A1 (https=)
CO (1) CO2023015805A2 (https=)
CR (1) CR20230530A (https=)
DO (1) DOP2023000247A (https=)
EC (1) ECSP23093673A (https=)
GE (1) GEAP202416419A (https=)
IL (1) IL308392A (https=)
JO (1) JOP20230291A1 (https=)
MX (1) MX2023013492A (https=)
PE (1) PE20240890A1 (https=)
TW (1) TW202313666A (https=)
WO (1) WO2022241287A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
US12281149B2 (en) * 2021-05-13 2025-04-22 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
JP2025530024A (ja) * 2023-01-18 2025-09-10 シャンハイ ミンウェイ バイオテクノロジー カンパニー，リミテッド 三重活性を有する融合タンパク質およびその応用
TW202500575A (zh) * 2023-05-21 2025-01-01 美商卡默療法股份有限公司 具有或不具有體重相關合併症之過重或肥胖成人之治療
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
US20260116848A1 (en) 2024-07-31 2026-04-30 Carmot Therapeutics Inc. Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists
WO2026027650A1 (en) 2024-08-02 2026-02-05 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-cyano-5-fluorophenyl)-2-methyl-propionic acid
WO2026073030A1 (en) 2024-09-27 2026-04-02 Carmot Therapeutics Inc. Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists
CN119930843B (zh) * 2025-01-22 2025-12-30 北京康乐卫士生物技术股份有限公司 具有glp和gip双重活性的融合蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534676A (ja) * 2014-09-24 2017-11-24 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
WO2019183577A1 (en) * 2018-03-23 2019-09-26 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
CN1364167A (zh) 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2001017568A2 (en) 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
AU2003278600A1 (en) 2002-11-01 2004-05-25 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
BR122019021416A2 (https=) 2003-09-19 2019-12-21
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
CA2607566A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
RS53230B (sr) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
WO2008021560A2 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
RU2454415C9 (ru) 2006-10-19 2013-02-27 Такеда Фармасьютикал Компани Лимитед Производное индола
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
JP2010517935A (ja) 2007-02-09 2010-05-27 武田薬品工業株式会社 Ｐｐａｒ−ガンマのパーシャルアゴニストとしての縮合環化合物
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
WO2011143365A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
US20120021979A1 (en) 2010-06-24 2012-01-26 Vanderbilt University GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
WO2012088379A2 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
DK2710031T3 (en) 2011-05-18 2018-01-02 Mederis Diabetes Llc IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
WO2013148579A1 (en) 2012-03-29 2013-10-03 Cebix Inc. Pegylated c-peptide
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
WO2014088432A1 (en) 2012-12-06 2014-06-12 Callaghan Innovation Research Limited Conjugate compounds
US9766239B2 (en) 2013-03-13 2017-09-19 Arizona Board Of Regents On Behalf Of Arizona State University Synbodies for detection of human norovirus
EP3604271A1 (en) 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptides for amino acid and peptide conjugates and conjugation process
WO2015031268A1 (en) 2013-08-26 2015-03-05 Arizona Board Of Regents On Behalf Of Arizona State University High affinity synbodies for influenza
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
EP3218414A1 (en) 2014-11-14 2017-09-20 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
TWI582109B (zh) 2015-01-09 2017-05-11 美國禮來大藥廠 Ｇｉｐ及ｇｌｐ－１共促效劑化合物
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
GB2551945B (en) 2015-12-18 2021-09-08 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
TWI799680B (zh) 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
EP4230640A4 (en) 2020-10-16 2024-11-20 Hanmi Pharm. Co., Ltd. GLP-1/GIP DOUBLE AGONIST, LONG-ACTING CONJUGATE THEREOF AND PHARMACEUTICAL COMPOSITION THEREOF
PE20231309A1 (es) 2020-10-17 2023-08-24 Sun Pharmaceutical Ind Ltd Agonistas duales glp-1/gip
CN114617956B (zh) 2020-12-10 2023-10-03 江苏中新医药有限公司 一种高效降糖的蛋白质药物
KR20220092442A (ko) 2020-12-24 2022-07-01 한미약품 주식회사 신규한 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도
US12281149B2 (en) * 2021-05-13 2025-04-22 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
WO2023028466A1 (en) 2021-08-23 2023-03-02 Eli Lilly And Company Compounds and methods for liquid phase synthesis
US20250223331A1 (en) 2021-09-02 2025-07-10 Sunshine Lake Pharma Co., Ltd. Glp-1/gip dual-targeted polypeptide and fusion protein and applications thereof
WO2023089594A1 (en) 2021-11-22 2023-05-25 Sun Pharmaceutical Industries Limited Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534676A (ja) * 2014-09-24 2017-11-24 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
WO2019183577A1 (en) * 2018-03-23 2019-09-26 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. Volume 296, Article 100133, JPN6026008917, 4 January 2021 (2021-01-04), pages 1 - 15, ISSN: 0005810823 *

Also Published As

Publication number Publication date
US12281149B2 (en) 2025-04-22
WO2022241287A2 (en) 2022-11-17
CL2023003369A1 (es) 2024-05-17
US20230151074A1 (en) 2023-05-18
ECSP23093673A (es) 2024-01-31
CO2023015805A2 (es) 2023-12-11
JOP20230291A1 (ar) 2023-11-13
DOP2023000247A (es) 2024-03-28
EP4337682A2 (en) 2024-03-20
TW202313666A (zh) 2023-04-01
CA3220005A1 (en) 2022-11-17
CN117980325A (zh) 2024-05-03
MX2023013492A (es) 2024-02-29
IL308392A (en) 2024-01-01
PE20240890A1 (es) 2024-04-24
WO2022241287A3 (en) 2022-12-29
AU2022272251A1 (en) 2023-11-16
GEAP202416419A (en) 2024-03-25
CR20230530A (es) 2024-02-19
US20240383960A1 (en) 2024-11-21
BR112023023559A2 (pt) 2024-02-06
KR20240007251A (ko) 2024-01-16

Similar Documents

Publication Publication Date Title
JP2024517942A (ja) Ｇタンパク質共役受容体の調節剤
TWI840348B (zh) G蛋白偶聯受體調節劑
JP2023513272A (ja) ヘテロ環ｇｌｐ－１アゴニスト
EP3105213B1 (en) Dihydrobenzofuran compounds useful in the treatment of diabetes and obesity
US20230295154A1 (en) Heterocyclic glp-1 agonists
JP6380402B2 (ja) ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
WO2024125602A1 (en) Salts and solid forms of a compound having glp-1 agonist activity
WO2025045208A1 (en) Heteroaryl-heterocycloalkyl-based glp-1 agonists
TW202506102A (zh) 雜環的glp-1促效劑
EA052579B1 (ru) Модуляторы сопряженных с g-белком рецепторов
EP3650440A1 (en) Benzoic ester compound
HK40085148B (zh) 杂环glp-1激动剂
EA051684B1 (ru) Модуляторы сопряженных с g-белком рецепторов
HK40022717A (en) Benzoic ester compound
HK1227023B (en) Dihydrobenzofuran compounds useful in the treatment of diabetes and obesity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260305